Omeprazole for Injection

Name: Omeprazole for Injection
Brand: Reyoung Pharmaceutical Co., Ltd.
SKU: 1946912872

Shandong, ChinaReyoung Pharmaceutical Co., Ltd.

Negotiable

20,000 vial

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

for Injection

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Powder

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

1vial/Box; 10vials/Box; 50vials/Box

Trademark

Reyoung

Origin

China Reyoung

Production Capacity

50million Vials/Year

Company profile

Reyoung Pharmaceutical Co., Ltd.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2020-10-13 CertifiedNearest Port: Qingdao PortAverage Response Time: >24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryReyoung Pharmaceutical Co., Ltd. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The available information identifies it as a pharmaceutical manufacturer supplying injectable antibiotics, oral solid medicines, veterinary cefotaxime sodium sterile, and lyophilized products. It reports more than 10 production lines, 370 years of combined R&D engineer experience, 50 quality-control staff, and ISO9001, ISO14001, and ISO45001 certifications. Export sales represent 31%–40% of total sales, with exporting reported since 2020 in one record and since 1998 in the company description, creating a discrepancy. Trade records show limited documented transactions and associated buyers in Bolivia, India, and Vietnam. Evidence is insufficient to assess after-sales service, financial credibility, customization, or verified customer performance comprehensively.

Supplier typeThe supplier is identified as a limited company and pharmaceutical manufacturer based in Shandong, China. Its stated products include injectable cephalosporins and penicillins, oral solid medicines, lyophilized products, and veterinary medicines, indicating a combined manufacturing and commercial business profile.

CertificationsThe supplier reports ISO9001:2015, ISO14001:2015, and ISO45001:2016 management-system certificates, along with cGMP, PIC/S, and ANVISA GMP holdings. These claims directly support established quality, environmental, occupational-safety, and pharmaceutical GMP capability, although certificate validity and scope are not independently shown.

R&D capabilityThe supplier reports 370 years of total R&D engineer experience and offers multiple dosage forms and pharmaceutical categories, including lyophilized products and injectable antibiotics. These details support R&D resources and product-development breadth, but no information confirms proprietary technologies, new product launches, patents, or development outcomes.

Production capacityProduction capability is supported by 4,950 employees, more than 10 production lines, pharmaceutical manufacturing descriptions, and product records for injectable antibiotics and veterinary cefotaxime sodium sterile. The plant-area entry is recorded as 0.0m², which is unusable or inconsistent data, so facility scale cannot be confirmed from that field.

Client casesTrade-related records associate the supplier with buyers in Bolivia, India, and Vietnam and show documented transactions for oral rehydration products, cefotaxime acid, and ceftriaxone sodium for injection. The records show some international commercial activity, but the number of stated transactions is limited and no customer testimonials, repeat-order evidence, or performance evaluations are provided.